# UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases

> **NCT07410377** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 15 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Inflammatory Myopathy

## Interventions

- **BIOLOGICAL:** UCAR-T cells

## Key facts

- **NCT ID:** NCT07410377
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-03
- **Final completion:** 2028-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07410377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07410377, "UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07410377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*